BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. (BCTX) Financial Performance & Income Statement Overview
Explore the financials of BriaCell Therapeutics Corp. (BCTX), including yearly and quarterly data on income, cash flow, and balance sheets.
BriaCell Therapeutics Corp. (BCTX) Income Statement & Financial Overview
View the income breakdown for BriaCell Therapeutics Corp. BCTX across both annual and quarterly reports.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $37867.00 | $36401.00 | $99215.00 | $5180.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | -$5180.00 |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $5.68M | $3.67M | $4.41M | $7.66M |
| SG&A Expenses | $1.48M | $1.49M | $1.36M | $1.57M |
| Operating Expenses | $7.17M | $5.15M | $5.77M | $9.23M |
| Total Costs & Expenses | $7.17M | $5.15M | $5.77M | $9.23M |
| Interest Income | $46832.00 | $13050.00 | $2.00 | $15606.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $37867.00 | $26657.00 | $72444.00 | $3816.00 |
| EBITDA | -$7.14M | -$5.13M | -$5.70M | -$9.23M |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$7.17M | -$5.15M | -$5.77M | -$9.23M |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $831615.00 | -$676444.00 | $4.52M | $10.92M |
| Income Before Tax | -$6.34M | -$5.83M | -$1.25M | $1.69M |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$10.98M |
| Net Income | -$6.29M | -$5.80M | -$1.21M | $1.72M |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | -$2.33 | -$0.32 | -$0.07 | $0.11 |
| Diluted EPS | -$2.33 | -$0.32 | -$0.07 | $0.11 |
| Weighted Avg Shares Outstanding | $2.70M | $18.03M | $18.03M | $15.98M |
| Weighted Avg Shares Outstanding (Diluted) | $2.70M | $18.03M | $18.03M | $15.98M |
The company's financials show resilient growth, with revenue advancing from $0.00 in Q3 2024 to $0.00 in Q2 2025. Gross profit remained healthy with margins at N/A in Q2 2025 compared to N/A in Q3 2024. Operating income hit -$7.17M last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$7.14M. Net income dropped to -$6.29M, while earnings per share reached -$2.33. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan